Trials / Completed
CompletedNCT00625495
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the effects of Nexium at a dose of 40mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole | 40mg Intravenous infusion over 3 minutes |
| DRUG | Esomeprazole | 40mg Oral |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2002-11-01
- Completion
- 2002-11-01
- First posted
- 2008-02-28
- Last updated
- 2011-01-24
Source: ClinicalTrials.gov record NCT00625495. Inclusion in this directory is not an endorsement.